培元抑瘤汤加减辅助治疗对晚期肺癌患者预后及血清肿瘤标志物的影响

Effect of Modified Peiyuan Yiliu Decocion Adjuvant Therapy on Prognosis and Serum Tumor Markers for Patients with Advanced Lung Cancer

目的:观察培元抑瘤汤加减辅助化疗对晚期肺癌患者预后及血清肿瘤标志物的影响。方法:选取我院2013年1月~2014年12月收治晚期肺癌患者52例,根据患者入院诊治时间顺序,将52例患者分为对照组及观察组,每组患者26例。两组患者均进行单药吉西他滨化疗,在化疗的基础中对照组患者采用常规支持治疗,观察组在对照组的基础上加用培元抑瘤汤加减辅助治疗。对两组患者治疗前后后血清癌胚抗原(CEA)、糖蛋白抗原125(CA-125)、细胞角蛋白-19可溶性片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、血清免疫球蛋白(IgG、IgM、IgA)、补体(C3)水平变化情况及对患者生存时间进行比较分析。结果:观察组患者化疗前后CEA、CA-125、CYFRA21-1、NSE水平无明显变化(P>0.05);对照组患者化疗后CEA、CA-125、CYFRA21-1水平较化疗前有明显变(P<0.05),其中CA-125、CYFRA21-1水平显著高于观察组患者,数据差异无统计学意义(P>0.05);观察组患者化疗后IgG、IgM、IgA及C3水平较化疗前有明显变化,呈现逐渐上升的趋势(P<0.05);观察组患者化疗后IgG、IgM、IgA及C3水平显著高于对照组患者(P<0.05);对照组患者中位OS估计值为15.361个月,观察组患者中位OS估计值为16.012个月,两组患者中位OS估计值差异无统计学意义(P>0.05)。结论:晚期肺癌患者使用培元抑瘤汤加减辅助化疗可有效提高患者免疫功能,更有利于稳定患者病情,值得临床推广及运用。

Objective： To explore the effect of Modified Peiyuan Yiliu Decocion Adjuvant Therapy on the prognosis and serum tumor markers for patients with advanced lung cancer. Methods： To select our hospital from January 2013 to December2013 were 52 cases patients with adanced lung cancer,according to the time sequence of diagnosis and treatment of patients admitted to hospital,the 52 patients were divided into controlled group and observation group,26 cases of each group of patients. Two groups of patients with single-agent gemcitabine chemotherapy,on the basis of chemotherapy in the controlled group were treated by routine support treatment,on the basis of the observation group in the controlled group used Modified Peiyuan Yiliu Decocion Adjuvant Therapy. After the two groups of patients before and after treatment serum carcinoembryonic antigen（ CEA）,glycoprotein antigen 125（ CA-125）,cytokeratin-soluble 19 fragment（ CYFRA21 - 1）,neuron specific enolization enzyme（ NSE）,serum immunoglobulin（ IgG,IgM and IgA）,complement（ C3） level and the changes of comparative analysis for patients survival time. Results： There was no significant change in CEA,Ca-125,CYFRA21 - 1,and NSE levels before and after chemotherapy in the observation group（ P〉0. 05）. The levels of CEA,ca-125 and CYFRA21 - 1 in the controlled group were significantly different from those before chemotherapy（ P〈 0. 05）,and the levels of CA-125 and CYFRA21 - 1 were significantly higher than those in the observation group,with no statistically significant difference（ P〉0. 05）. The levels of IgG,IgM,IgA and C3 in the observation group were significantly different from those before chemotherapy,showing a gradual increase（ P〈0. 05）. The levels of IgG,IgM,IgA and C3 in the observation group were significantly higher than those in the controlled group（ P 〈0. 05）. The median OS estimate in the controlled group was 15. 361 months, and the median OS estimate in the observation group was16. 012 months,and there was no significant difference in the median OS estimation between the two groups（ P〉0. 05）. Conclusion： Patients with advanced lung cancer can effectively improve the immune function of patients,which is more conducive to stable patient＇s disease,and is worthy of clinical promotion and application.